Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotorasib plus panitumumab versus investigator's choice in previously treated KRAS p.G12C metastatic colorectal cancer
jRCT2011210078Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sotorasib and panitumumab in colorectal cancer (CRC) and colorectal adenocarcinoma (3 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Apr 2022; status: completed.
02
Drugs
sotorasibpanitumumab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2011210078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210078.